Sewer sampling, the authors say, could be expanded to track other infectious diseases such as H5N1 avian flu or mpox or to detect unexpected pathogens.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
With deaths at the lowest point in about 2 years and cases declining, the WHO urged countries to keep a close eye on cases and virus changes.
Following the reappearance of Ebola in the Democratic Republic of the Congo's (DRC's) Equateur province, the country today launched an rVSV-EBOV vaccine campaign, tapping an initial shipment of 200 doses, the World Health Organization (WHO) African regional office said today.
The roadmap "will provide a framework for the development of broadly protective coronavirus vaccines to ensure that we are prepared to respond" to future SARS-CoV-2 variants or other viruses with pandemic potential.
Also, federal officials are taking steps to make sure Pfizer's COVID-19 pill, Paxlovid, will be widely available across the US.
Israelis aged 60 and older given a fourth dose of the Pfizer/BioNTech COVID-19 vaccine amid the Omicron surge had a 64% lower risk of hospitalization and 78% lower risk of death than those who received three doses, suggests an observational study published yesterday in Nature Medicine.
Two thirds of family members restricted from visiting loved ones in the ICU had symptoms of PTSD 3 months later.
Data show a 36% to 68% lower risk of a COVID-19 hospital stay with Omicron.
US cases, now nearing 50,000 per day, are rising fastest in the Midwest and Northeast.
A modeling study estimates that COVID-19 vaccination prevented more than 1.5 million infections, 72,000 hospitalizations, and 19,000 deaths in the first 10 months of vaccination in California, according to a study published late last week in JAMA Network Open.
Also, the WHO revised its assessment of remdesivir, recommending it for mild or moderate infections in high-risk groups.
